Catalyst Wire Dossier Catalyst Wire Dossier

Bimatoprost Ophthalmic Solution 0.01%

bimatoprost · Mankind Pharma Limited
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Bimatoprost Ophthalmic Solution 0.01%, covering 2022-08-10 to 2022-12-13. Get the full timeline:

Most recent: Clinical Trial Update: Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma [Phase 3]

See pricing